NEWS RELEASE-Elpiscience

Choose Language : EN

EN CN

EN | CN

NEWS RELEASE

HOME - NEWS RELEASE

01 May 2018

Elpiscience and Inhibrx Announce an Exclusive Collaboration and License Agreement of INBRX-106 (ES102) in Greater China Shanghai and San Diego, May 1, 2018, Elpiscience Biopharmaceutical Ltd (Elpiscience) has entered into a licensing agreement with Inhibrx, Inc., pursuant to which Elpiscience was granted an exclusive r...
01 March 2018

Elpiscience and Inhibrx Announce an Exclusive Collaboration and License Agreement of INBRX-105 (ES101) in Greater China Shanghai and San Diego, March 01, 2018, Elpiscience Biopharmaceutical, Ltd. (Elpiscience), a biotech company focusing on the discovery and development of next-generation cancer immunotherapies, announ...
08 October 2017

Elpiscience Announces Inauguration in Zhangjiang Shanghai, October 8, 2017, Elpiscience, a start-up biopharma focusing on cancer immunotherapies, announces that it officially starts the operation in Zhangjiang High-Tech Park. Elpiscience was founded...
30 August 2017

Elpiscience Completes Series A Financing of 20 Million USD Shanghai, August 30, 2017, Elpiscience announces it has raised 20 million USD in series A financing, invested by Lilly Asia Ventures (LAV). Elpiscience intends to use the proceeds from the financing t...
25 June 2017

Elpiscience Announces the Establishment of Board of Directors Shanghai, June 25, 2017. Elpiscience has established its board of directors and held the first meeting in Shanghai. Board members include Darren Ji (co-founder, CEO), Hongtao Lu (co-founder, CSO), Dav...

上一页3/3下一页